glp 1 glucagon GLP-1 Medications – Community Education Glucagon-like Peptide 1, Glucose-Dependent Insulinotropic

5- other GLP-1 trials in Parkinsons have been statistically negative or the results unclear, 6- the study was conducted in only very early Parkinsons cases, 7- the data, if replicable, may not be generalizable to all GLP-1 agonist drugs or to all subtypes of Parkinsons, and 8- the drug Lixisenatide requires a DAILY injection

[DOI] [PubMed] [Google Scholar] 875.Banting F.G., Best C.H., Collip J.B., Campbell W.R., Fletcher A.A

Coincidentally, the patient had started on semaglutide just before the start of her history of chronic UTIs

The evidence presented here is meant to inform that decision, not make it for you

Advance equitable access and shape policy : GLP-1 medications have the potential to significantly benefit populations with lower socioeconomic status, yet these groups often face the greatest barriers to access

They panic when side effects spike after a dose increase, not realizing the previous dose is still building in their system